ADMA Biologics Inc. (ADMA) |
|
2.85 -0.08 (-2.73%)
|
07-01 16:00 |
|
Open: |
2.9 |
Pre. Close: |
2.93 |
|
High:
|
2.94 |
Low:
|
2.83 |
|
Volume:
|
2,815,853 |
Market Cap:
|
246M |
|
|
|
|
ADMA Biologics, Inc., a biopharmaceutical and specialty immunoglobulin company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States. It offers BIVIGAM, an intravenous immune globulin product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB, which is indicated for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It also develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, the company operates source plasma collection facilities. The company distributes its products through independent distributors, sales agents, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
2.944 - 2.965 |
2.965 - 2.981 |
|
Low:
|
2.777 - 2.804 |
2.804 - 2.826 |
|
Close:
|
2.812 - 2.849 |
2.849 - 2.878 |
|
Technical analysis |
as of: 2020-07-01 4:29:46 PM |
|
Overall:
|
 |
| Stoxline posted a SELL today, same as yesterday. Downward movement continues. |
| Target: |
Six months: 3.67 One year: 3.97 |
| Support: |
Support1: 2.73 Support2: 2.27 |
| Resistance: |
Resistance1: 3.14 Resistance2: 3.40 |
| Pivot: |
2.94  |
| Moving Average: |
MA(5): 2.93 MA(20): 2.96
MA(100): 2.91 MA(250): 3.72 |
| MACD: |
MACD(12,26): Signal(9): 0.02 |
| Stochastic oscillator: |
%K(14,3): 45.59 %D(3): 51.96 |
| RSI: |
RSI(14): 46.70 |
| 52-week: |
High: 5.48 Low: 1.45 Change(%): -20.6 |
| Average Vol(K): |
3-Month: 274718 10-Days: 239640 |
|
Price, moving averages and Bollinger Bands |
|
Price and moving averages has closed below its Short term moving average. Short term moving average is currently above mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.ADMA has closed above bottom band by 20.8%. Bollinger Bands are 71.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to ADMA's normal range. The bands have been in this narrow range for 17 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Headline News |
Fri, 26 Jun 2020
ADMA Biologics Inc. (ADMA) recently have taken one step ahead with the beta value of 2.06 - News Daemon
Thu, 25 Jun 2020
Fresh Data-Based Insight On ADMA Biologics, Inc. (ADMA) - Stocks Register
Thu, 25 Jun 2020
ADMA Biologics Inc (ADMA) Stock: Buy, Hold, or Sell? - InvestorsObserver
Wed, 24 Jun 2020
Analysts Say ADMA Biologics, Inc. (NASDAQ:ADMA) Can Really Get to $15 in 12 Months - Marketing Sentinel
Tue, 23 Jun 2020
Hedge Funds Have Never Been This Bullish On ADMA Biologics Inc (ADMA) - Yahoo Finance
Tue, 23 Jun 2020
BRIEF-ADMA Biologics Announces Martha J. Demski Elected To Board Of Directors - Reuters
|
Financial Analysis |
| Growth |
 |
| Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing. |
| Profitability |
 |
| Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs. |
| Solvency |
|
| Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry. |
| Efficiency |
|
| Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not. |
| Click here to get more fundamental analysis.
|
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ Capital Market |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. (M) |
86 |
| Shares Float (M) |
68 |
|
% Held by Insiders
|
7.35 |
|
% Held by Institutions
|
47.91 |
|
Shares Short (K)
|
9,210 |
|
Shares Short P. Month (K)
|
9,680 |
Stock Financials |
|
EPS
|
-0.890 |
|
EPS Est This Year
|
-1.740 |
|
EPS Est Next Year
|
-1.080 |
|
Book Value (p.s.)
|
1.120 |
|
Profit Margin
|
-151.18 |
|
Operating Margin
|
-124.89 |
|
Return on Assets (ttm)
|
-19.5 |
|
Return on Equity (ttm)
|
-102.4 |
|
Qtrly Rev. Growth
|
189.1 |
|
Gross Profit (p.s.)
|
-0.118 |
|
Sales Per Share
|
0.417 |
|
EBITDA (p.s.)
|
-0.483 |
|
Qtrly Earnings Growth
|
|
|
Operating Cash Flow (M)
|
-87 |
|
Levered Free Cash Flow (M)
|
-70 |
Stock Valuations |
|
PE Ratio
|
-3.20 |
|
PEG Ratio
|
|
|
Price to Book value
|
2.54 |
|
Price to Sales
|
6.83 |
|
Price to Cash Flow
|
-2.84 |
Stock Dividends |
|
Dividend
|
|
|
Forward Dividend
|
|
|
Dividend Yield
|
|
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
7 Binary Options
|
|
Your Ad Here
|
|
